RhumbLine Advisers’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16.6M | Buy |
157,413
+2,463
| +2% | +$218K | 0.01% | 810 |
|
|
2025
Q4 | $13.5M | Sell |
154,950
-9,030
| -6% | -$739K | 0.01% | 923 |
|
|
2025
Q3 | $10.9M | Sell |
163,980
-9,048
| -5% | -$514K | 0.01% | 1045 |
|
|
2025
Q2 | $9.56M | Buy |
173,028
+10,963
| +7% | +$526K | 0.01% | 1072 |
|
|
2025
Q1 | $7.84M | Buy |
162,065
+101
| +0.1% | +$4.23K | 0.01% | 1128 |
|
|
2024
Q4 | $6.25M | Sell |
161,964
-2,214
| -1% | -$96.5K | 0.01% | 1315 |
|
|
2024
Q3 | $7.39M | Buy |
164,178
+79,203
| +93% | +$3.2M | 0.01% | 1212 |
|
|
2024
Q2 | $2.94M | Sell |
84,975
-14
| -0% | -$410 | ﹤0.01% | 1681 |
|
|
2024
Q1 | $2.46M | Buy |
84,989
+1,697
| +2% | +$46.2K | ﹤0.01% | 1801 |
|
|
2023
Q4 | $1.91M | Buy |
83,292
+483
| +0.6% | +$8.45K | ﹤0.01% | 1929 |
|
|
2023
Q3 | $1.38M | Buy |
82,809
+4,898
| +6% | +$95K | ﹤0.01% | 2035 |
|
|
2023
Q2 | $2.15M | Buy |
77,911
+3,202
| +4% | +$80.1K | ﹤0.01% | 1862 |
|
|
2023
Q1 | $1.72M | Buy |
74,709
+3,556
| +5% | +$59.7K | ﹤0.01% | 1883 |
|
|
2022
Q4 | $776K | Buy |
71,153
+636
| +0.9% | +$5.37K | ﹤0.01% | 2263 |
|
|
2022
Q3 | $594K | Buy |
70,517
+3,951
| +6% | +$37.4K | ﹤0.01% | 2415 |
|
|
2022
Q2 | $527K | Buy |
66,566
+20,140
| +43% | +$244K | ﹤0.01% | 2476 |
|
|
2022
Q1 | $1.1M | Buy |
46,426
+2,457
| +6% | +$69.2K | ﹤0.01% | 2098 |
|
|
2021
Q4 | $1.5M | Buy |
43,969
+1,274
| +3% | +$40.3K | ﹤0.01% | 2030 |
|
|
2021
Q3 | $757K | Buy |
42,695
+1,883
| +5% | +$80.3K | ﹤0.01% | 2355 |
|
|
2021
Q2 | $1.83M | Buy |
40,812
+7,597
| +23% | +$251K | ﹤0.01% | 1996 |
|
|
2021
Q1 | $860K | Sell |
33,215
-520
| -2% | -$13.2K | ﹤0.01% | 2251 |
|
|
2020
Q4 | $680K | Buy |
33,735
+4,289
| +15% | +$92.3K | ﹤0.01% | 2312 |
|
|
2020
Q3 | $576K | Sell |
29,446
-230
| -0.8% | -$4.32K | ﹤0.01% | 2222 |
|
|
2020
Q2 | $524K | Buy |
29,676
+13,005
| +78% | +$163K | ﹤0.01% | 2322 |
|
|
2020
Q1 | $118K | Buy |
16,671
+380
| +2% | +$2.85K | ﹤0.01% | 2739 |
|
|
2019
Q4 | $115K | Buy |
16,291
+751
| +5% | +$7.46K | ﹤0.01% | 2861 |
|
|
2019
Q3 | $187K | Buy |
15,540
+2,662
| +21% | +$33.5K | ﹤0.01% | 2767 |
|
|
2019
Q2 | $156K | Buy |
+12,878
| New | +$142K | ﹤0.01% | 2849 |
|
|
2018
Q2 | – | Sell |
-10,294
| Closed | -$88K | – | 2926 |
|
|
2018
Q1 | $88K | Buy |
+10,294
| New | +$194K | ﹤0.01% | 2762 |
|
|
2017
Q4 | – | Sell |
-10,096
| Closed | -$178K | – | 2853 |
|
|
2017
Q3 | $178K | Buy |
10,096
+20
| +0.2% | +$277 | ﹤0.01% | 2779 |
|
|
2017
Q2 | $114K | Buy |
+10,076
| New | +$108K | ﹤0.01% | 2883 |
|
Other funds holding PTGX
FCM
RI
VPM
VCM
JJ
RhumbLine Advisers's PTGX Position: Q1 2026 in Review
RhumbLine Advisers increased its Protagonist Therapeutics (PTGX) stake by 1.6% in Q1 2026, buying an estimated $218K and bringing the position to 157,413 shares worth $16.6M. The position accounts for 0.01% of the portfolio, ranked #810.
RhumbLine Advisers first reported a position in PTGX in Q2 2017 and has held it in 31 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.
- RhumbLine Advisers held 157,413 shares of Protagonist Therapeutics worth $16.6M as of Q1 2026.
- RhumbLine Advisers bought 2,463 Protagonist Therapeutics shares in Q1 2026, an estimated $218K.
- Protagonist Therapeutics made up 0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #810 holding.
- RhumbLine Advisers first reported a position in Protagonist Therapeutics in Q2 2017 and has held it in 31 quarters since.
- 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.
Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.